# Peptide Vaccinations Plus GM-CT-01 in Melanoma

> **NCT01723813** · PHASE1,PHASE2 · TERMINATED · sponsor: **Cliniques universitaires Saint-Luc- Université Catholique de Louvain** · enrollment: 6 (actual)

## Conditions studied

- Metastatic Melanoma

## Interventions

- **BIOLOGICAL:** Tumor specific peptides: MAGE-3.A1 and / or NA17.A2
- **BIOLOGICAL:** Galectin-3 inhibitor: GM-CT-01 systemic injections
- **BIOLOGICAL:** Galectin-3 inhibitor: GM-CT-01 Peri-tumoral administration

## Key facts

- **NCT ID:** NCT01723813
- **Lead sponsor:** Cliniques universitaires Saint-Luc- Université Catholique de Louvain
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-04
- **Primary completion:** 2015-04-01
- **Final completion:** 2015-04-01
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** due to end of validity of peptide vaccine
- **Last updated:** 2019-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01723813

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01723813, "Peptide Vaccinations Plus GM-CT-01 in Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01723813. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*